Detalhe da pesquisa
1.
Author Correction: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cell.
Nat Immunol
; 25(5): 925-926, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38514890
2.
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.
Nat Immunol
; 18(9): 1004-1015, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28759001
3.
Advancing translational research for colorectal immuno-oncology.
Br J Cancer
; 129(9): 1442-1450, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563222
4.
In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours.
Immunol Cell Biol
; 92(2): 156-63, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24217808
5.
Role of the microbiota in response to and recovery from cancer therapy.
Nat Rev Immunol
; 2023 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932511
6.
A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.
Cell Rep Med
; 4(3): 100971, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871558
7.
siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.
Immunol Cell Biol
; 90(2): 187-96, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21423261
8.
OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice.
FASEB Bioadv
; 3(10): 829-840, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34632317
9.
The composition of the gut microbiota following early-life antibiotic exposure affects host health and longevity in later life.
Cell Rep
; 36(8): 109564, 2021 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433065
10.
The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota.
Cell Rep Med
; 2(12): 100464, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028606
11.
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
J Immunother Cancer
; 8(2)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199513
12.
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.
Cancer Immunol Res
; 7(4): 559-571, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30894377
13.
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.
Oncoimmunology
; 7(7): e1445949, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29900061
14.
No evidence of durable trained immunity after two doses of adenovirus-vectored or mRNA COVID-19 vaccines.
J Clin Invest
; 133(17)2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37471143
15.
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Clin Cancer Res
; 22(21): 5183-5188, 2016 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27620276
16.
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.
Oncoimmunology
; 5(7): e1192740, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622048
17.
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.
Cancer Res
; 76(21): 6266-6277, 2016 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27634762
18.
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Cancer Discov
; 6(12): 1382-1399, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663893
19.
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Cancer Cell
; 30(3): 391-403, 2016 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622332
20.
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.
Cancer Res
; 76(18): 5288-301, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503925